REG - Avacta Group PLC - Director/PDMR Shareholding <Origin Href="QuoteRef">AVTG.L</Origin>
RNS Number : 5552OAvacta Group PLC21 August 201721 August 2017
Avacta Group plc
("Avacta", the "Group" or the "Company")
Director/PDMR Shareholding
Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and research reagents, announces that its Chief Executive Officer, Dr Alastair Smith has today purchased 33,225 ordinary shares of 10p each ("Ordinary Shares") at a price of 74.5p per share.
Following this transaction, Dr Smith's total beneficial interest in the Group is 570,509 Ordinary Shares, representing approximately 0.8% of Avacta's issued share capital. In addition, Alastair Smith has a joint interest in 1,640,000 shares in the share capital of the Company; such shares are jointly held by certain Directors individually and Avacta Group Trustee Limited in its capacity as trustee of The Avacta Employees' Share Trust.
Enquiries:
Avacta Group plc
Alastair Smith, Chief Executive Officer
Tony Gardiner, Chief Financial Officer
Tel: +44 (0) 844 414 0452
finnCap Ltd
Geoff Nash / Giles Rolls - Nominated Adviser
Tim Redfern / Alice Lane - Corporate Broking
WG Partners
David Wilson
Nigel Barnes
Claes Spang
Tel: +44 (0) 207 220 0500
www.finncap.com
Tel: +44 (0) 203 705 9318
Tel: +44 (0) 203 705 9217
Media Enquiries
FTI Consulting
Simon Conway / Natalie Garland-Collins
Tel: +44 (0) 203 727 1000
Notes to Editors
Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.
Antibodies dominate markets worth in excess of $50bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.
The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1.
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Alastair Smith
2.
Reason for the Notification
a)
Position/status
Chief Executive Officer
b)
Initial notification/Amendment
Initial notification
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Avacta Group Plc
b)
LEI
n/a
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the Financial instrument, type of instrument
Ordinary shares of 10p
Identification code
GB00BYYW9G87
b)
Nature of the transaction
Purchase of ordinary shares
c)
Price(s) and volume(s)
Price(s)
Volume(s)
74.5 pence
33,225
d)
Aggregated information:
Aggregated volume
Price
See above
e)
Date of the transaction
21 August 2017
f)
Place of the transaction
London Stock Exchange, AIM Market (XLON)
This information is provided by RNSThe company news service from the London Stock ExchangeENDDSHOKDDPKBKDCFB
Recent news on Avacta
See all newsRCS - Avacta Group PLC - Investor Webinar
AnnouncementREG - Avacta Group PLC - Update on AVA6000 Phase 1a Clinical Trial Progress
AnnouncementREG - AIM - AIM Notice - 19/03/2024
AnnouncementREG - Avacta Group PLC - Result of General Meeting
AnnouncementREG - Avacta Group PLC - Avacta Announces AVA6000 Poster at AACR
Announcement